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Abstract
Background: As a harm reduction strategy in response to HIV epidemics needle and syringes programs (NSPs)
were initiated throughout China in 2002. The effectiveness of NSPs in reducing the spread of infection in such an
established epidemic is unknown. In this study we use data from Yunnan province, the province most affected by
HIV in China, to (1) estimate the population benefits in terms of infections prevented due to the programs; (2)
calculate the cost-effectiveness of NSPs.
Methods: We developed a mathematical transmission model, informed by detailed behavioral and program data,
which accurately reflected the unique HIV epidemiology among Yunnan injecting drug users (IDUs) in the
presence of NSPs. We then used the model to estimate the likely epidemiological and clinical outcomes without
NSPs and conducted a health economics analysis to determine the cost-effectiveness of the program.
Results: It is estimated that NSPs in Yunnan have averted approximately 16-20% (5,200-7,500 infections) of the
expected HIV cases since 2002 and led to gains of 1,300-1,900 DALYs. The total $1.04 million spending on NSPs
from 2002 to 2008 has resulted in an estimated cost-saving over this period of $1.38-$1.97 million due to the
prevention of HIV and the associated costs of care and management.
Conclusion: NSPs are not only cost-effective but cost-saving in Yunnan. Significant scale-up of NSPs interventions
across China and removal of the societal and political barriers that compromise the effects of NSPs should be a
health priority of the Chinese government.
Keywords: HIV injecting drug users, Yunnan, China, needle-syringe programs, mathematical model, health
economics
Background
HIV epidemics in Asia were initially driven by injecting
drug use and sex work. Waves of infection have histori-
cally occurred in these population groups, followed by
infection among clients of sex workers and their regular
sexual partners [1,2]. The first recognizable HIV out-
break in China occurred among injecting drug users
(IDUs) in the city of Ruili, Yunnan province in 1989 [3],
following which the epidemic rapidly expanded through-
out Yunnan and neighboring provinces. By 2009, an
estimated 740,000 people were infected with HIV in
China, including 105,000 with AIDS [4]. Yunnan, a
multi-ethnic province of China with a long history of
opium and heroin trade and high prevalence of illicit
drugs [5], have accounted for over one-quarter of all
HIV cases in China [6,7]. HIV in Yunnan has primarily
spread through intravenous drug use with a high annual
incidence rate of 2.2%-8.0% [8]. These intravenous drug
users are young and approximately 80% of them are in
their 20 s and 30 s [9]. In 2002, over a decade after the
epidemic commenced, needle and syringes programs
(NSPs) were initiated by various agencies throughout
China as a harm reduction strategy. Currently it is esti-
mated that more than 100 needle and syringe exchange
sites are operating throughout Yunnan province alone
and a total of 2.5 million syringes were distributed in
2008 [10,11]. Despite the large investment in NSPs, it is
estimated that less than 25% of IDUs in Yunnan obtain
their injecting equipment through NSPs [12,13] and
rates of sharing of injecting equipment remains as high
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effective means to reduce HIV transmission in some
developed and developing country settings [15-20].
Therefore, it is important to investigate whether the
same degree of effectiveness has been achieved in miti-
gating the spread of infection in a setting such as China,
with an established HIV epidemic among IDUs.
In this study we aim to (1) estimate the population
benefits that NSPs in Yunnan have likely had in pre-
venting HIV infections and related health outcomes
among IDUs; (2) calculate the cost-effectiveness of NSPs
from a governmental perspective. We estimate the
expected number of infections averted due to NSPs
through the development of a mathematical transmis-
sion model. The model uses data on the numbers of
units of injecting equipment distributed by Yunnan
NSPs and behavioral and clinical data from Yunnan pro-
vince (such as rates of needle sharing between IDUs,
rates of disposal of used needles, frequency of injecting,
natural history of HIV disease progression in infected
IDUs, initiation of antiretroviral therapy), coupled with
biological data from the international literature and
local HIV epidemiological data. The model is calibrated
to accurately reflect the unique HIV epidemiology (inci-
dence, prevalence and aggregate reported number of
relevant clinical outcomes including deaths) among
Y u n n a nI D U sa n dt h e ni ti su s e dt oe s t i m a t et h el i k e l y
epidemiological and clinical outcomes if NSPs were not
present. We also conduct a health economics analysis
by comparing the financial costs associated with imple-
m e n t i n gN S P sw i t ht h ec o s t ss a v e dd u et oa v e r t i n g
infections to determine how cost-effective the program
has been from a societal perspective. We consider the
cost-effectiveness over the last 7 years and also lifetime
value of the program.
Method
A mathematical transmission model was developed to
describe the HIV epidemic among IDUs in Yunnan. The
model is based on a system of ordinary differential
equations [21] and is used to track the rates of HIV
transmission from infected IDUs to susceptible IDUs
through injecting-related risk behavior and the natural
history of infection for HIV-infected individuals as pre-
sented in the schematic diagram in Figure 1. This is
well-developed epidemiological model that has been
used in numerous occasions and has been shown to
accurately reflect the dynamic of HIV epidemic [21].
This standard schematic diagram is mathematically
translated into 4 ordinary differential equations, one
equation for each health state. The health states repre-
sented in the model are: uninfected and potentially sus-
ceptible individuals (S), and HIV-infected individuals
that are either in the asymptomatic chronic stage (I),
treatment-eligible stage (CD4 count < 200 cells/μl) (TE)
or are receiving antiretroviral treatment (T). The differ-
ential equations to describe the change in the number
of people in each of these disease states are:
Rate of change in the
number of uninfected
people

dS
dt
=
New people enter
population

π −
Per - capita rate of
HIV transmission.
Depends on risk - related
behavior and prevalence of
HIV among partners

λS −
Death rate for
uninfected people

μSS
(1)
Rate of change in the
number of
chronic - stage cases

dI
dt
=
Per - capita rate of
HIV transmission 
λS −
Rate of disease progression
from chronic infection
to treatment - eligible stage

ηI −
Death rate for
HIV - infected people
in chronic stage

μcI
(2)
Rate of change
in the number of
treatment - eligible
AIDS cases 
dTE
dt
=
Rate of disease
progression from
chronic infection to
treatment - eligible
stage

ηI +
Rate of people
on ART
stopping treatment

σT −
Rate of diagnosed
people in AIDS stage
initiating treatment

τTE −
Death rate for
HIV - infected people
in treatment - eligible
stage

μaTE
(3)
Rate of change
in the number
of people on ART

dT
dt
=
Rate of diagnosed
people in AIDS stage
initiating treatment

τTE −
Rate of people
on ART
stopping treatment

σT −
Death rate for
people on ART

μtT
(4)
As such, the model tracks the numbers of HIV-
infected people as they progress in disease through the
long chronic/asymptomatic infection to late-stage
Figure 1 Schematic diagram of the flow between health states
described in the mathematical model.
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gression to late-stage infection (CD4 count < 200 cells/
μl [22]) and this is what is described in this model. The
rates of disease progression are assumed to be constant
over time and represent population average rates. Effec-
tive antiretroviral therapy (ART) is assumed to reduce
viral load in treated individuals and consequently
decrease the likelihood of transmitting the virus (by 95%
on average, assuming the same relative reduction in
infectiousness as in other modes of transmission [23]).
The number of IDUs in the population is defined as N
and it is assumed that each IDU injects an average of n
times per year. A proportion, s,o fa l lI D U sm a ys h a r e
their syringes with others and they do so in a propor-
tion, q, of their injections. It is assumed that if sharing
of injecting equipment occurs then it happens between
two IDUs. The probability of infection from a contami-
nated syringe per use is denoted as bI,b u tp e o p l ew h o
are on treatment are expected to have a lower probabil-
ity of transmission bT due to suppressed viral load [23].
In the model, syringe cleaning has effectiveness εC and
cleaning occurs before an average proportion of pC
shared injections. Given these definitions, the proportion
of sharing events in total per person per year is nsq/2
and each susceptible person could acquire infection with
probability (1 - pCεC) bI or (1 - pCεC)bI depending on
the HIV stage of his/her injecting partner. Therefore,
considering the proportion of the entire population in
each disease stage, the force of infection l, which esti-
mates the average per-capita risk of infection [21], can
then be calculated as
λ =
nsqβI(1 − pcεc)
2
I
N
+
nsqβI(1 − pcεc)
2
TE
N
+
nsqβT(1 − pcεc)
2
T
N (5)
Official figures over the past decade indicate that the
number of registered drug users in Yunnan varies
between 50,000-70,000, among which ~55% are IDUs
[14,24,25]. The actual number of IDUs may be much
higher as it is widely accepted that in China there are
approximately 4 implicit IDUs behind every registered
IDU [26,27]. In this study a sensitivity analysis is carried
out on the IDU population size such that the number of
IDUs is (i) 2.5 times the registered number; or (ii) 4
times the registered number.
IDUs in Yunnan may obtain syringes through both
commercial means and NSPs, but the majority (~75-
95%) are obtained commercially [12,13]). Therefore, we
assume that the majority of NSP-based distribution of
sterile needles and syringes adds to the total numbers
that are in circulation. If PM and PN commercial and
NSP syringes are distributed each year through these
means, respectively, and a proportion ω of all syringes
are not used, then the number of syringes distributed
that are used is (PM + PN)(1 - ω). In this model it is
assumed that syringe distribution by NSPs (PN)
increases linearly since its initiation but commercial syr-
inge distribution (PM) remained constant throughout
these years. If a non-shared needle is used δp times on
average before disposal and a shared needle is used an
average of δs times before disposal then
(PM + PN)(1 − ω)=
nN
δpδs

δs − sq

δs − δp
	
(6)
defines a relationship between the total number of
needles distributed and their use. This relationship was
defined previously by Kwon et al [15]. Several factors
may change due to changes in the number of needles
distributed. These include: the proportion of syringes
that remain unused (ω), the proportion of IDUs who
share injecting equipment (s) and the prevalence of
sharing injecting equipment (q), or the average number
of times each syringe is used before it is disposed (δp,
δs). Changes in ω and δp will not influence transmission
levels of the virus but changes in s, q and δs could
potentially result in significant changes in HIV inci-
dence. Previous studies have demonstrated that the
average number of times a syringe is used before it is
disposed varies very little [28-31] and that IDUs are
unlikely to share if they have access to clean injecting
equipment [32]; therefore, it is assumed that sharing
rates (q) change with syringe distribution (according to
equation (6)) and other values remain constant. Para-
meter estimates used in the model are presented in
Table 1.
The model was solved in Matlab and numerical solu-
tions yielded estimates of: the annual number of new
HIV incident cases, the number of treatment-eligible
HIV patients, the number of people on ART, the num-
ber of HIV/AIDS-related deaths, and the total size of
the HIV-infected population under conditions of actual
distribution of needles and syringes by NSPs and pre-
dicted estimates if NSPs had not existed. The model
was calibrated to reflect available epidemiological data,
mainly HIV prevalence. The calibration was performed
by adjusting biological and epidemiological parameters
inside the model within their corresponding uncer-
tainty bounds until the model-generated HIV preva-
lence curve closely mimics the trend of actual data.
Retrospectively the model was then used to estimate
the expected trajectories of the HIV epidemic in China
in the absence of NSPs under the assumption that the
reduced number of units of injecting equipment
affected sharing rates (according to the supply-demand
relationship of equation 6). We estimated the number
of disability-adjusted life years (DALYs) gained, and
number of HIV cases and deaths averted due to NSPs
in Yunnan.
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estimate the cost-effectiveness of the programs for both
periods of 2002-2008 and lifetime of IDUs. The lifetime
economic impacts of NSPs are evaluated by summing
the future costs of currently survived HIV-infected IDUs
beyond 2008, without consideration of new future infec-
tions. The epidemiological model results became inputs
in the health economic analysis. The amount of money
invested in NSPs was compared with the estimated
costs saved due to averting infections that would have
resulted in expenses for monitoring, care, treatment.
The costs of NSPs during the period 2002-2008 is calcu-
lated by multiplying the average unit expense of distri-
buting a syringe ($0.11 USD), which incorporates and
averages over all necessary infrastructure, personnel,
marketing and recurring service costs [33], to the esti-
mated total number of syringes distributed. A conserva-
tive approach was taken with the inclusion of costs
Table 1 Input values for the mathematical model
Parameter Description Values References
Biological transmission parameters
b Probability of HIV transmission per injection with a contaminated syringe 0.001 - 0.005 [50-57]
h Rate of disease progression from chronic infection to treatment-eligible stage 11-15% [58]
μc Death rate for HIV-infected people in chronic stage 0.06-0.11% [59,60]
μa Death rate for HIV-infected people in treatment-eligible stage 3.00-7.86% [59,60]
μt Death rate for people on ART 0.06-0.11% [59,60]
Τ Rate of diagnosed people on AIDS stage initiating treatment 0-10% estimated
a
s Rate of people on ART stopping treatment 15-20% [61,62]
Epidemiology and NSP parameters
p(t) Prevalence among IDUs in Yunnan province 20-30% [9]
N Population size of IDUs in Yunnan province SF = 2.5 95,000-125,000 estimated
b
SF = 4.0 150,000-200,000
π Rate of new entrants into the IDU population 6000 estimated
c
Pn Total number of syringes distributed through NSP per year (2002-2008) 8.75 × 10
6 personal communication
d
R Percentage of syringes obtained through NSPs 5-25% [12,13]
ω Percentage of syringes distributed that are not used 0.5-1% Assumption
Behavioral parameters
n Average frequency of injecting per IDU per year (weighted average of daily and non-daily
injectors)
300-800 [12,31,63-65]
s Proportion of IDUs who share syringes 40-90% [12,14,31,66-69]
q Proportion of injections that are shared for IDUs that share syringes 29.4% [66]
δt Average number of times each syringe is used before disposal 2-4 [28-31]
δp Average number of times each non-shared syringe is used before disposal 1-3 estimated
e
δs Average number of times each shared syringe is used before disposal 3-15 estimated
e
Syringe cleaning parameters
Pc Proportion of syringes used multiple times by multiple people that are cleaned before re-
use
20-40% [12,70]
εc Effectiveness of syringe cleaning 70-80% [71,72]
a. This number is estimated by dividing the number of HIV-infected IDUs initiating ART each year by the total number of IDUs who live with HIV. It is important
to note that ART is only initiated after 2004, hence τ = 0 prior to 2004. We estimated that approximately 10% IDUs are on ART in 2008 and assumed a linear
growth of percentage between 2004 and 2008.
b. In Yunnan, official figures indicate that the number of registered drug users varies between 50,000 to 70,000 in the last decade [73-75]. Among these
registered drug users, 55% are intravenous drug users period [14,24,25], which corresponds to an increase of ~30,000 to ~40,000 registered IDUs in the last
decade. It is widely accepted that in China behind every registered IDUs there is about 2.5-4.0 implicit IDUs that are unregistered [26,27]. The total number of
IDUs in Yunnan is estimated to lie between 95,000 and 125,000 if the scaling factor equals to 2.5, whereas the population size is between 150,000 and 200,000 if
scaling factor equals to 4.
c. The entrance rate of IDUs is calculated from the variation of population size, whose minimum and maximum bounds are estimated to be 30,000 and 50,000 over
the period 2002-2008 based on the above scenarios. Therefore, an average entrance rate is estimated to be 6000.
d. The cumulative number of syringes distributed in Yunnan during the period 2002-2008 is approximately 875,000. This number is obtained through personal
communication with stakeholders from China CDC.
e. Given that the average usage of a syringe (δt) among Yunnan IDUs is about 3 [28-31], the average usage of a non-shared syringe (δP) is assumed to be less
than 3 and greater than 1. Therefore, the average usage of a shared syringe (δS) can then be estimated to be 3-15 by equation δt = s·q·δs +( 1-sq)·δP.
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and any antiretroviral treatment programs that were
supported or subsidized by the Chinese government
under its “four free one care” policy [34]. The costs of
t h ep r o g r a m sw e r ec a l c u l a t e db ym u l t i p l y i n gt h eu n i t
price of service items, which are determined from pub-
lished literature and policy documents, to the quantities
of provision (Table 2). All costs associated with program
investment, infection, treatment and care are listed in
Table 2. Undiscounted and 3% discounting analyses
were performed.
Results
The epidemiological model accurately resembles the epi-
demiological trends of HIV prevalence in Yunnan dur-
ing the past decade (Figure 2, 3). The model estimates
that according to scaling factor (SF) assumptions of the
total IDU population size being 2.5-times (Figure 2) or
4-times (Figure 3) the number of registered IDUs,
approximately 20,712 or 37,970 new HIV infections
have occurred among IDUs during the period of NSPs,
respectively. The model also estimated that NSPs have
averted 5,263 (SF = 2.5; 7,541 for SF = 4) new HIV
Table 2 Summary of economic results
2002-2008 2002-Lifetime
Cumulative number of cases W/o NSPs With NSPs Averted W/o NSPs With NSPs Averted
DALYs
a (SF = 2.5) 44,391 43,007 1,384 128,879 116,126 12,753
(SF = 4.0) 76,606 74,628 1,978 225,854 207,582 18,272
HIV incidence (SF = 2.5) 25,975 20,712 5,263 25,975 20,712 5,263
(SF = 4.0) 45,511 37,970 7,541 45,511 37,970 7,541
Number of total infected patients in 2008 (SF = 2.5) 35,741 30,998 4,743 35,741 30,998 4,743
(SF = 4.0) 63,111 56,313 6,797 63,111 56,313 6,797
Number of patients on ART in 2008 (SF = 2.5) 1,800 1,739 61 1,800 1,739 61
(SF = 4.0) 3,107 3,020 87 3,107 3,020 87
Number of TE patients (person-years) (SF = 2.5) 58,664 57,815 849 174,166 158,819 15,347
(SF = 4.0) 100,675 99,462 1,213 304,298 282,308 21,990
Number of patients on ART (person-years) (SF = 2.5) 3,083 3,025 58 68,004 60,483 7,522
(SF = 4.0) 5,307 5,224 83 119,487 108,710 10,777
Governmental investment (millions, in 2009 dollars with 3% discount)
Total NSP investment
b – $1.04 m –– $1.04 m –
Expenses stratified by service items
Viral load tests
c (SF = 2.5) $1.03 m $1.01 m $0.02 m $15.43 m $13.86 m $1.57 m
(SF = 4.0) $1.77 m $1.74 m $0.03 m $27.06 m $24.81 m $2.25 m
CD4 load tests
d (SF = 2.5) $21.96 m $21.10 m $0.85 m $50.80 m $45.97 m $4.83 m
(SF = 4.0) $38.00 m $36.78 m $1.22 m $88.99 m $82.07 m $6.92 m
Provision of ART
e (SF = 2.5) $10.29 m $10.09 m $0.19 m $154.31 m $138.57 m $15.74 m
(SF = 4.0) $17.71 m $17.43 m $0.27 m $270.60 m $248.05 m $22.55 m
Subsidies on Treatment of OIs
f (SF = 2.5) $26.40 m $26.04 m $0.36 m $61.77 m $57.14 m $4.63 m
(SF = 4.0) $45.29 m $44.77 m $0.51 m $107.59 m $100.95 m $6.63 m
Subsidies on Chinese herbal treatment
g (SF = 2.5) $1.24 m $1.23 m $0.02 m $2.91 m $2.69 m $0.22 m
(SF = 4.0) $2.13 m $2.11 m $0.02 m $5.06 m $4.75 m $0.31 m
Total expenses associated with infection (SF = 2.5) $60.91 m $59.47 m $1.44 m $285.22 m $258.23 m $26.99 m
(SF = 4.0) $104.89 m $102.83 m $2.06 m $499.30 m $460.63 m $38.66 m
Expenses stratified by target groups
Expenses on HIV asymptomatic patients
h (SF = 2.5) $14.86 m $14.11 m $0.75 m $26.90 m $24.09 m $2.80 m
(SF = 4.0) $25.82 m $24.74 m $1.08 m $47.26 m $43.24 m $4.02 m
Expenses on AIDS patients
i (SF = 2.5) $34.16 m $33.70 m $0.46 m $79.94 m $73.95 m $5.99 m
(SF = 4.0) $58.61 m $57.94 m $0.66 m $139.23 m $130.65 m $8.58 m
Expenses on AIDS patients on ART
j (SF = 2.5) $11.89 m $11.67 m $0.22 m $178.38 m $160.19 m $18.19 m
(SF = 4.0) $20.47 m $20.15 m $0.32 m $312.81 m $286.75 m $26.06 m
Total expenses associated with infection (SF = 2.5) $60.91 m $59.47 m $1.44 m $285.22 m $258.23 m $26.99 m
(SF = 4.0) $104.89 m $102.83 m $2.06 m $499.30 m $460.63 m $38.66 m
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= 4) of infections without NSPs and resulted in a gain
of 1,384 (SF = 2.5; 1,978 for SF = 4) DALYs, and will
gain a further 12,753 (SF = 2.5; 18,272 for SF = 4)
DALYs in the patients’ lifetimes. In addition, an extra
849 (SF = 2.5; 1,213 for SF = 4) person-years in the
AIDS stage have likely been averted by NSPs and a
further 15,347 (SF = 2.5; 21,990 for SF = 4) person-years
will be saved in the patients’ lifetimes due to the lasting
effects of the implemented program. NSPs have led to
an estimated 41% (SF = 2.5; 32% for SF = 4) decline in
annual HIV incidence in 2008.
Since the initiation of NSPs in Yunnan in 2002, about
875,000 syringes were distributed throughout the pro-
vince, costing USD$1.04 m. The total expenditure for
the care, management and treatment of HIV-infected
people since 2002 was USD$59.47 m (SF = 2.5; USD
$102.83 m for SF = 4) (3% discounting), of which 56%
were spent on treatment-eligible patients who are not
yet receiving antiretroviral therapy (ART), whereas the
remainder was spent on asymptomatic patients (24%)
and those on ART (20%). However, if NSPs did not
exist, the model estimates that the Chinese government
would have spent an extra USD$1.44 m (SF = 2.5; USD
$2.06 m for SF = 4) on HIV/AIDS patients care and
management over the past decade due to the higher
HIV incidence. Since this saving of healthcare expenses
is greater than the initial investment, these programs are
n o to n l yv e r yc o s t - e f f e c t i v eb u tc o s t - s a v i n ge v e no v e r
this short time period. The investment in NSPs in Yun-
nan since 2002 will yield even greater savings in the
long term. In the lifetime of the current population, the
benefits of averting infections over the last 10 years will
lead to large future savings, of USD$27 m (SF = 2.5; $39
m for SF = 4) (3% discounting) over the population
lifetime.
The return on investment of the NSPs in Yunnan was
also assessed with a cost-utility analysis. It is estimated
that the cost for each DALY gained since 2002 is
approximately USD$753 (SF = 2.5; USD$527 for SF =
4), but the value reduces to USD$82 (SF = 2.5; USD$57
for SF = 4) if the lifetime impacts of the program are
considered. Healthcare programs are generally consid-
ered cost-effective if the cost per DALY saved is less
than the per capita gross national income (GNI) [35].
The Chinese per-capita GNI is USD$3,650 in 2009 [36].
Additionally, with an estimate of NSP investment 1.04
million, the directly gained economic benefit is mea-
sured to be 1.4-2.0 million during 2002-2008, which cor-
responds to a benefit-cost ratio of 1.38-1.97 (SF = 2.5, 4
respectively, Table 2). Thus, this program is extremely
cost-effective compared to most healthcare programs. In
Table 2 Summary of economic results (Continued)
Cost Benefit Analysis
Cost/DALY averted (SF = 2.5) $753 $82
(SF = 4.0) $527 $57
Benefit-cost ratio (ratio of expenses saved to investment) (SF = 2.5) 1.38 25.89
(SF = 4.0) 1.97 37.09
Cost/Infection averted (SF = 2.5) $198 $198
(SF = 4.0) $138 $138
a. The cumulative numbers of DALYs are calculated based on the values of health utilities at different disease stages. Health utilities among asymptomatic people
living HIV, people at AIDS stage and patients receiving ART are 0.88 (0.82-0.94) [76,77], 0.64 (0.58-0.70) [77] and 0.78 (0.76-0.80) [76,78] respectively.,
b. The costs of NSPs during the period 2002-2008 is calculated by multiplying the average unit expense of distributing a syringe ($0.11 USD), which incorporates
and averages over all necessary infrastructure, personnel, marketing and recurring service costs [33], to the estimated total number of syringes distributed (8.75 ×
10
6).
c. Regular viral load monitoring is currently undertaken once a year for HIV/AIDS patients on ART to monitor potential change in viral load. Its cost is hence the
product of the number of patients on ART and its unit cost (~USD$300/person [79,80]) and is calculated with 3% value discounting.
d. CD4 load tests are performed quarterly for patients on ART [80-82] and twice a year for people diagnosed with HIV but not on ART [80,82]. The unit cost of
CD4 load test is USD $42 [83]. The total cost is calculated with 3% discounting.
e. The annual cost of ART for each AIDS patient is approximately USD $3000 [83-86], which is multiplied by the number of patients on ART to obtain the total
cost. The total cost is calculated with and without value discounting.
f. Each year, the government subsidizes approximately USD $340 [87] of healthcare associated with opportunistic infections of symptomatic AIDS patients (those
that are in the treatment-eligible stage or potentially on ART (but experienced treatment failure) in our model). Its total yearly spending is calculated as the
product of the two with 3% value discounting.
g. Each year, the government subsidizes approximately USD $16 [87] of herbal treatment for each symptomatic AIDS patient (treatment-eligible patients and
patients on ART). Its total yearly spending is calculated as the product of the two with and without value discounting.
h. Each HIV asymptomatic patients are CD4 tested twice a year [80,82], the governmental investment on each individual HIV patients is USD$42 × 2 = USD$84.
This amount is multiplied by the total number of asymptomatic patients and then summed with the cost of one-off diagnosis testing of newly infected cases to
result in the total governmental investment in this specific target group.
i. Each HIV-infected patient yet to receive ART will receive CD4 testing twice each year [80,82]. Treatment of opportunistic infections and Chinese herbal
treatment for AIDS are also covered or subsidized by the government [87].
Each patient on ART will receive 1 viral test and 4 CD4 tests each year [79-82]. In addition to government-subsidized treatment for opportunistic infections and
herbal treatment for AIDS, they also receive ART on governmental expenses [85].
Zhang et al. BMC Public Health 2011, 11:250
http://www.biomedcentral.com/1471-2458/11/250
Page 6 of 11fact, not only are NSPs in Yunnan cost-effective, but we
have calculated that they are actually cost-saving. That
is, the return in healthcare savings is greater than the
initial investment. Specifically, for every one dollar the
government invested into NSPs, it was estimated the
government would gain back that dollar plus an addi-
tional USD$0.38 (SF = 2.5; USD$0.97 for SF = 4) due to
the reduced number of HIV-related tests and treat-
ments. The return on investment is even greater when
the lifetime effects of these programs are taken into
account: ~USD$15 (SF = 2.5; USD$36 for SF = 4) are
returned for every USD$1 invested over the past 7
years. We also estimated that it cost USD$198 (SF =
2.5; USD$138 for SF = 4) of investment into NSPs to
avert a new HIV infection.
Discussion
We estimated that the spending of a total USD$1.04
million on NSPs from 2002 to 2008 has resulted in
cost-savings of USD$1.38-1.97 million due to the pre-
vention of HIV and the associated costs of care and
management. During the same time period more than
1,300-1,900 DALYs and more than 5,200-7,500 infec-
tions have been saved. Lifetime projections suggest that
continued substantial savings of costs and gains in years
of life would occur. Even though there is an established
HIV epidemic and HIV transmission has likely contin-
ued at moderately high levels, NSPs in Yunnan are still
shown to be very effective in reducing the total number
of HIV transmissions among IDUs, averting approxi-
mately 16-20% of the potential HIV cases since 2002.
Figure 2 Results of epidemiological model with IDU population size scaling factor 2.5 times the registered number of IDUs. (a) Extracted
published prevalence data [9] and model-based estimates of HIV prevalence among IDUs in Yunnan with and without NSPs; (b) model-based
estimates of HIV incidence among IDUs in Yunnan with and without NSPs; (c) Estimated cumulative number of HIV infections averted due to NSPs;
(d) Estimated cumulative number of AIDS deaths, people on ART, and people in treatment-eligible stage averted due to NSPs.
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Page 7 of 11This is comparable to a similar investigation carried out
in 2006 in Ukraine over its one year harm reduction
intervention, which consequently lead to a 22% decrease
in IDU HIV incidence and 1% decrease in prevalence
[16]. IDU-initiated HIV epidemics remain as confined
epidemics and have not yet generalized to other popula-
tions in China.
The current study is an important study that evaluated
the cost-effectiveness of NSPs for IDUs in China. We
have shown the programs to be cost-saving. The fact
that the benefit-cost ratio increases substantially over
t h el i f e t i m eo ft h ep o p u l a t i on reflects the long-term
impacts of the programs. Our estimate of USD$138-198
in spending per infection averted is consistent with simi-
lar studies in other locations [16,37,38]. By adjusting the
cost to account for the purchasing power parity for
China (2007 PPP factor was 4.09 relative to 1 USD), the
cost translates to $560-810 per infection averted, which
is still very cost-effective in comparison to many devel-
oped countries ($3,000-$20,000 [39-42]).
Our analysis involved a conservative calculation of the
cost-effectiveness of NSPs by only including governmen-
tal investment in HIV/AIDS alone. The actual savings
will be much higher for a number of reasons. First, hepa-
titis C virus (HCV) has a very high prevalence among
Chinese IDUs (55-80% [43,44]). A 2009 report on the
cost-effectiveness of Australian NSPs demonstrated that
the majority of savings by NSPs are actually due to HCV-
related healthcare expenses saved and not HIV [45]. Sec-
ond, other medical costs such as those due to mental
Figure 3 Results of epidemiological model with IDU population size scaling factor 4.0 times the registered number of IDUs. (a) Extracted
published prevalence data [9] and model-based estimates of HIV prevalence among IDUs in Yunnan with and without NSPs; (b) model-based
estimates of HIV incidence among IDUs in Yunnan with and without NSPs; (c) Estimated cumulative number of HIV infections averted due to NSPs;
(d) Estimated cumulative number of AIDS deaths, people on ART, and people in treatment-eligible stage averted due to NSPs.
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Page 8 of 11health episodes, injecting related injury, psychosocial
benefits, overdose education and prevention may further
increase the return on investment. Third, we did not
include patient/client costs or productivity losses or
gains. AIDS patients are contributing a substantial out-
of-pocket payment while accessing government-sup-
ported services, including transportation to clinic/hospi-
tal, consultation fees and hospitalization expenses.
Therefore, our calculations should be regarded as a very
conservative estimate of the actual expenses saved.
Several limitations of the current study should be
noted. First, the cost data used in this study was col-
lected from a number of sources from Yunnan and
also other provinces [39-45]. Treatment-related cost
variations may occur due to differences in economic
development in different provinces. However, these dif-
ferences are considered to be small as the treatment
prices are standardized in governmental health institu-
tions under the national “four free one care” policy.
Second, the current study is based on ART eligibility
at a CD4 threshold of 200 cells/μl. China has recently
adopted a new guideline to initiate treatment at 350
cells/μl [46]. This will likely significantly increase the
potential medical expenses for ART patients in their
lifetime. Besides, the current study does not take into
consideration of secondary impacts of NSPs, e.g.
reduction of infections among sexual partners of IDUs
due to decrease of HIV prevalence among IDUs as a
result of NSPs. Therefore, our analysis should be
regarded as a conservative estimate of the actual cost-
effectiveness of NSPs in Yunnan. Third, this study
used a simple deterministic approach and did not
include a detailed uncertainty analysis. However, we
took into consideration the variation in IDU popula-
tion size, which represents the largest and most impor-
tant uncertain parameter. Results from this analysis
should be regarded as an estimation of the average
effectiveness and cost-effectiveness of NSPs in Yunnan.
Finally, a notable limitation of the current epidemiolo-
gical model is that it does not include the quitting rate
of IDUs, which may vary the population size substan-
tially. We assume that an IDU leaves the population
only through death.
The current coverage of NSPs in the province remains
low, as less than 25% of IDUs access NSPs. This sug-
gests that it is possible to have even greater health and
economic gains by expanding the programs further in
the future. Large changes in government attitudes
occurred from viewing drug users as criminals to large-
scale adoption of needle and syringe provision [47].
Ongoing police raids and confinement of drug users
cause increasing fear of police arrest and reluctance to
access to sterile equipment from NSP sites or peer edu-
cators. Compulsory detention of IDUs in China in
detoxification centers and labor camps largely limits the
accessibility of IDUs to NSPs [48,49]. Hence, enhancing
cooperation between multiple institutions including the
Ministry of Health and Public Security and Justice is
necessary for further scale-up of the programs. Other
issues include reducing social stigma against drug users
and maintaining users’ anonymity in NSP sites. If such
barriers can be removed and NSPs expanded then there
is strong potential for the large epidemiological and eco-
nomic benefits to increase even more substantially.
Whilst these results are specific to Yunnan, China, the
qualitative conclusions are generally applicable to other
settings that are considering commencing or expanding
NSPs where HIV is endemic among IDUs. NSPs not
only save lives and health outcomes but they are also a
valuable economic investment.
Conclusion
Conclusively, NSPs are not only cost-effective but cost-
saving in Yunnan since the implementation of the pro-
grams and will have greater epidemiological and eco-
nomic benefits if in the life span of IDUs. Significant
scale-up of NSPs interventions across China and
removal of the societal and political barriers that com-
promise the effects of NSPs should be a health priority
of the Chinese government.
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